Clinical Trial Update: 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma [NA]

View source ↗

Summary

Clinical trial update describing the imaging agent 68Ga-FAPI-46 for staging pancreatic adenocarcinoma, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 68Ga-FAPI-46 (Gallium-68-labeled FAPI-46)

Snippet

Sponsor: Centre Hospitalier Universitaire Vaudois | Conditions: Pancreatic Adenocarcinoma, PET / CT | NA | Status: NOT_YET_RECRUITING